Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1959 1
1971 1
1978 2
1991 1
1993 1
1995 1
2001 2
2002 2
2003 1
2004 1
2008 1
2009 1
2010 2
2011 1
2012 1
2013 1
2018 2
2019 1
2020 2
2021 4
2022 1
2023 2
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

33 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean viguer mt (1 results)?
[Hip controversies].
Nordin JY, Siguier M, Bonnevialle P, Chiron P, Laude F, Nourissat C, Musset T, Hernigou P, Fillipini P, Farizon F. Nordin JY, et al. Rev Chir Orthop Reparatrice Appar Mot. 2008 Oct;94 Suppl(6):S200-10. doi: 10.1016/j.rco.2008.07.254. Epub 2008 Sep 25. Rev Chir Orthop Reparatrice Appar Mot. 2008. PMID: 18928816 Review. French. No abstract available.
HIV preexposure prophylaxis: An essential, safe and effective prevention tool for sexual health.
Siguier M, Molina JM. Siguier M, et al. Med Mal Infect. 2018 Aug;48(5):318-326. doi: 10.1016/j.medmal.2018.01.009. Epub 2018 Feb 9. Med Mal Infect. 2018. PMID: 29433965 Review.
Preexposure prophylaxis of HIV with antiretroviral drugs is a prevention tool available in France since 2016, combined with the prevention methods already used (condoms, post-exposure treatment, rapid treatment of diagnosed HIV infections, etc.). It is targeted at populati …
Preexposure prophylaxis of HIV with antiretroviral drugs is a prevention tool available in France since 2016, combined with the prevention …
Rare predicted loss-of-function variants of type I IFN immunity genes are associated with life-threatening COVID-19.
Matuozzo D, Talouarn E, Marchal A, Zhang P, Manry J, Seeleuthner Y, Zhang Y, Bolze A, Chaldebas M, Milisavljevic B, Gervais A, Bastard P, Asano T, Bizien L, Barzaghi F, Abolhassani H, Abou Tayoun A, Aiuti A, Alavi Darazam I, Allende LM, Alonso-Arias R, Arias AA, Aytekin G, Bergman P, Bondesan S, Bryceson YT, Bustos IG, Cabrera-Marante O, Carcel S, Carrera P, Casari G, Chaïbi K, Colobran R, Condino-Neto A, Covill LE, Delmonte OM, El Zein L, Flores C, Gregersen PK, Gut M, Haerynck F, Halwani R, Hancerli S, Hammarström L, Hatipoğlu N, Karbuz A, Keles S, Kyheng C, Leon-Lopez R, Franco JL, Mansouri D, Martinez-Picado J, Metin Akcan O, Migeotte I, Morange PE, Morelle G, Martin-Nalda A, Novelli G, Novelli A, Ozcelik T, Palabiyik F, Pan-Hammarström Q, de Diego RP, Planas-Serra L, Pleguezuelo DE, Prando C, Pujol A, Reyes LF, Rivière JG, Rodriguez-Gallego C, Rojas J, Rovere-Querini P, Schlüter A, Shahrooei M, Sobh A, Soler-Palacin P, Tandjaoui-Lambiotte Y, Tipu I, Tresoldi C, Troya J, van de Beek D, Zatz M, Zawadzki P, Al-Muhsen SZ, Alosaimi MF, Alsohime FM, Baris-Feldman H, Butte MJ, Constantinescu SN, Cooper MA, Dalgard CL, Fellay J, Heath JR, Lau YL, Lifton RP, Maniatis T, Mogensen TH, v… See abstract for full author list ➔ Matuozzo D, et al. Genome Med. 2023 Apr 5;15(1):22. doi: 10.1186/s13073-023-01173-8. Genome Med. 2023. PMID: 37020259 Free PMC article.
Therefore, the determinants of life-threatening COVID-19 remain to be identified in ~ 80% of cases. METHODS: We report here a genome-wide rare variant burden association analysis in 3269 unvaccinated patients with life-threatening COVID-19, and 1373 unvaccinated SARS-CoV-2 …
Therefore, the determinants of life-threatening COVID-19 remain to be identified in ~ 80% of cases. METHODS: We report here a genome- …
Immunomodulators for immunocompromised patients hospitalized for COVID-19: a meta-analysis of randomized controlled trials.
Siempos II, Kalil AC, Belhadi D, Veiga VC, Cavalcanti AB, Branch-Elliman W, Papoutsi E, Gkirgkiris K, Xixi NA, Kotanidou A, Hermine O, Porcher R, Mariette X; CORIMUNO-19 Collaborative Group; DisCoVeRy Study Group; ACTT-2 Study Group; ACTT-3 Study Group. Siempos II, et al. EClinicalMedicine. 2024 Feb 9;69:102472. doi: 10.1016/j.eclinm.2024.102472. eCollection 2024 Mar. EClinicalMedicine. 2024. PMID: 38361992 Free PMC article.
We assessed the effect of immunomodulators on outcomes of immunocompromised patients hospitalized for COVID-19. METHODS: The protocol was prospectively registered with PROSPERO (CRD42022335397). ...
We assessed the effect of immunomodulators on outcomes of immunocompromised patients hospitalized for COVID-19. METHODS: The protocol …
Daily multidisciplinary COVID-19 meeting: Experiences from a French university hospital.
Rolland-Debord C, Canellas A, Choinier P, Milon A, Debrix I, Blin E, Belaube N, Mattioni S, Millet F, Nadal M, Petit-Hoang C, Rigaud P, Rech JS, Siguier M, Sroussi D, Denis M, Amiel C, Fartoukh M, Georgin-Lavialle S, Lassel L, Parrot A, Cadranel J. Rolland-Debord C, et al. Respir Med Res. 2021 May;79:100828. doi: 10.1016/j.resmer.2021.100828. Epub 2021 May 7. Respir Med Res. 2021. PMID: 34023794 Free PMC article.
Our aim was to describe our initial institutional standard operating procedures for implementing these meetings, and their impact on daily practice. METHODS: All consecutive patients who were hospitalized in our institution due to COVID 19, from March 31 to April 15, 2020, …
Our aim was to describe our initial institutional standard operating procedures for implementing these meetings, and their impact on daily p …
A noncemented total hip prosthesis.
Judet R, Siguier M, Brumpt B, Judet T. Judet R, et al. Clin Orthop Relat Res. 1978 Nov-Dec;(137):76-84. Clin Orthop Relat Res. 1978. PMID: 743847
Incidence and factors associated with PrEP discontinuation in France.
Garofoli N, Siguier M, Robineau O, Valette M, Phung B, Bachelard A, Rioux C, Le Gac S, Digumber M, Pialoux G, Ghosn J, Champenois K. Garofoli N, et al. J Antimicrob Chemother. 2024 May 17:dkae133. doi: 10.1093/jac/dkae133. Online ahead of print. J Antimicrob Chemother. 2024. PMID: 38758214
Our objective was to estimate the incidence of PrEP discontinuation and describe the reasons and factors associated with discontinuations. METHODS: A retrospective cohort was conducted in three French hospitals between January 2016 and June 2022. ...
Our objective was to estimate the incidence of PrEP discontinuation and describe the reasons and factors associated with discontinuations. …
First year of pre-exposure prophylaxis implementation in France with daily or on-demand tenofovir disoproxil fumarate/emtricitabine.
Siguier M, Mera R, Pialoux G, Ohayon M, Cotte L, Valin N, Ghosn J, Cua E, Pintado C, Chas J, Barriere G, Durand F, Molina JM. Siguier M, et al. J Antimicrob Chemother. 2019 Sep 1;74(9):2752-2758. doi: 10.1093/jac/dkz220. J Antimicrob Chemother. 2019. PMID: 31219561
We report the results of the first year of PrEP implementation in France. METHODS: Data were collected by physicians using a secured web subject-monitoring interface, with two forms: an initiation form, with patients' baseline characteristics, and an HIV seroconversion for …
We report the results of the first year of PrEP implementation in France. METHODS: Data were collected by physicians using a secured …
33 results